Literature DB >> 19788587

Genetic variation in CXCL12 and risk of cervical carcinoma: a population-based case-control study.

S N Maley1, S M Schwartz, L G Johnson, M Malkki, Q Du, J R Daling, S S Li, L P Zhao, E W Petersdorf, M M Madeleine.   

Abstract

CXCL12 provides a chemotactic signal-directing leucocyte migration and regulates metastatic behaviour of tumour cells. We conducted a population-based case-control study to test the hypothesis that common genetic variation in CXCL12 individual single nucleotide polymorphism (SNP) alleles and haplotypes] is associated with the risk of cervical carcinoma. Cases (n = 917) were residents of western Washington State diagnosed with invasive squamous cell cervical carcinoma (SCC), invasive adenocarcinoma or adenosquamous carcinoma, or adenocarcinoma in situ of the cervix. Control participants (n = 849) were identified from the source population by random digit telephone dialling and frequency matched to cases on county and age. Nine CXCL12 tagSNPs chosen from the SeattleSNPs database were genotyped. The minor allele of intronic SNP rs266085 was inversely associated with cervical cancer under a recessive genetic effects model (OR = 0.74, 95% CI: 0.56-0.98). Among the ten common haplotypes inferred from the nine tagSNPs, one haplotype defined by minor alleles at 5'-flanking SNP rs17885289 and rs266085, and common alleles at the other seven SNPs occurred among 7.8% of cases and 10.6% of controls (dominant model OR = 0.72, 95% CI: 0.56-0.93; recessive model OR = 0.35, 95% CI: 0.12-0.97; and log-additive model OR = 0.72, 95% CI: 0.57-0.90). A stepwise procedure identified rs17885289, rs266085 and 3'-untranslated region (UTR) SNP rs266093 as the most parsimonious subset of SNPs necessary to define the haplotype inversely associated with cervical cancer risk in our study. A 3'-UTR SNP, rs1801157, previously found to be related to HIV pathogenesis, was not associated with cervical cancer risk. Further population-based studies are warranted to confirm these associations between genetic variation in CXCL12 and cervical cancer risk.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19788587      PMCID: PMC2784202          DOI: 10.1111/j.1744-313X.2009.00877.x

Source DB:  PubMed          Journal:  Int J Immunogenet        ISSN: 1744-3121            Impact factor:   1.466


  42 in total

1.  Human papillomaviruses.

Authors: 
Journal:  IARC Monogr Eval Carcinog Risks Hum       Date:  2007

2.  The effect of stromal cell-derived factor 1 (SDF1/CXCL12) genetic polymorphism on HIV-1 disease progression.

Authors:  Edna Maria Vissoci Reiche; Maria Angelica Ehara Watanabe; Ana Maria Bonametti; Helena Kaminami Morimoto; Arilson Akira Morimoto; Susana Lilian Wiechmann; Jose Wander Breganó; Tiemi Matsuo; Fernando Vissoci Reiche; Helen Cristina Miranda; Karen Brajão Oliveira; Ingridt Hildegard Vogler; Alexandra Regina Siscar
Journal:  Int J Mol Med       Date:  2006-10       Impact factor: 4.101

3.  Correlation of interleukin-10 gene haplotype with hepatocellular carcinoma in Taiwan.

Authors:  L-H Tseng; M-T Lin; W-Y Shau; W-C Lin; F-Y Chang; K-L Chien; J A Hansen; D-S Chen; P-J Chen
Journal:  Tissue Antigens       Date:  2006-02

Review 4.  CXCR4: a key receptor in the crosstalk between tumor cells and their microenvironment.

Authors:  Jan A Burger; Thomas J Kipps
Journal:  Blood       Date:  2005-11-03       Impact factor: 22.113

5.  Analysis of CXCL12 3'UTR G>A polymorphism in colorectal cancer.

Authors:  M Hidalgo-Pascual; J J Galan; M Chaves-Conde; J A Ramírez-Armengol; C Moreno; E Calvo; P Pelaez; C Crespo; A Ruiz; J L Royo
Journal:  Oncol Rep       Date:  2007-12       Impact factor: 3.906

6.  Comprehensive analysis of HLA-A, HLA-B, HLA-C, HLA-DRB1, and HLA-DQB1 loci and squamous cell cervical cancer risk.

Authors:  Margaret M Madeleine; Lisa G Johnson; Anajane G Smith; John A Hansen; Brenda B Nisperos; Sue Li; Lue-Ping Zhao; Janet R Daling; Stephen M Schwartz; Denise A Galloway
Journal:  Cancer Res       Date:  2008-05-01       Impact factor: 12.701

Review 7.  Chemokine receptors in cancer metastasis and cancer cell-derived chemokines in host immune response.

Authors:  Keiichi Koizumi; Shozo Hojo; Takuya Akashi; Kazuo Yasumoto; Ikuo Saiki
Journal:  Cancer Sci       Date:  2007-11       Impact factor: 6.716

8.  CXCL12 G801A polymorphism is a risk factor for sporadic prostate cancer susceptibility.

Authors:  Hiroshi Hirata; Yuji Hinoda; Nobuyuki Kikuno; Ken Kawamoto; Angela V Dahiya; Yutaka Suehiro; Yuichiro Tanaka; Rajvir Dahiya
Journal:  Clin Cancer Res       Date:  2007-09-01       Impact factor: 12.531

9.  Genetic variation of antigen processing machinery components and association with cervical carcinoma.

Authors:  Akash M Mehta; Ekaterina S Jordanova; Tom van Wezel; Hae-Won Uh; Willem E Corver; Kitty M C Kwappenberg; Willem Verduijn; Gemma G Kenter; Sjoerd H van der Burg; Gert J Fleuren
Journal:  Genes Chromosomes Cancer       Date:  2007-06       Impact factor: 5.006

10.  Study on CXCR4/SDF-1alpha axis in lymph node metastasis of cervical squamous cell carcinoma.

Authors:  J-P Zhang; W-G Lu; F Ye; H-Z Chen; C-Y Zhou; X Xie
Journal:  Int J Gynecol Cancer       Date:  2007 Mar-Apr       Impact factor: 3.437

View more
  10 in total

1.  CXCL12 G801A polymorphism and cancer risk: An updated meta-analysis.

Authors:  Dan Meng; Yin-Xiang Wu; Vidhi Heerah; Shuang Peng; Meng-di Chu; Yong-Jian Xu; Wei-Ning Xiong; Shu-Yun Xu
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2015-06-14

2.  Association between SDF1-3'A or CXCR4 gene polymorphisms with predisposition to and clinicopathological characteristics of prostate cancer with or without metastases.

Authors:  Ferruh K Işman; Canan Kucukgergin; Selçuk Daşdemir; Bedia Cakmakoglu; Oner Sanli; Sule Seckin
Journal:  Mol Biol Rep       Date:  2012-10-11       Impact factor: 2.316

3.  CXCL12 chemokine and CXCR4 receptor: association with susceptibility and prognostic markers in triple negative breast cancer.

Authors:  Alda Losi Guembarovski; Roberta Losi Guembarovski; Bruna Karina Banin Hirata; Glauco Akelinghton Freire Vitiello; Karen Mayumi Suzuki; Mayara Tiemi Enokida; Maria Angelica Ehara Watanabe; Edna Maria Vissoci Reiche
Journal:  Mol Biol Rep       Date:  2018-06-20       Impact factor: 2.316

4.  CXCL12 G801A polymorphism is associated with an increased risk of benign salivary gland tumors in the Chinese population.

Authors:  Weijia Liu; Enxin Zhu; Ru Wang; Lihong Wang; Tingjiao Liu
Journal:  Med Oncol       Date:  2011-02-05       Impact factor: 3.064

5.  CXCL12 rs266085 and TNF-α rs1799724 polymorphisms and susceptibility to cervical cancer in a Chinese population.

Authors:  Geping Yin; Tongyu Zhu; Juan Li; Aifang Wu; Jing Liang; Yuanyuan Zhi
Journal:  Int J Clin Exp Pathol       Date:  2015-05-01

6.  Association of rs1801157 single nucleotide polymorphism of CXCL12 gene in breast cancer in Pakistan and in-silico expression analysis of CXCL12-CXCR4 associated biological regulatory network.

Authors:  Samra Khalid; Rumeza Hanif
Journal:  PeerJ       Date:  2017-09-15       Impact factor: 2.984

7.  Identification of differential plasma miRNA profiles in Chinese workers with occupational lead exposure.

Authors:  Ming Xu; Zhengmin Yu; Feifei Hu; Hongbing Zhang; Lixin Zhong; Lei Han; Yan An; Baoli Zhu; Hengdong Zhang
Journal:  Biosci Rep       Date:  2017-10-31       Impact factor: 3.840

Review 8.  Cervical Carcinogenesis and Immune Response Gene Polymorphisms: A Review.

Authors:  Akash M Mehta; Merel Mooij; Ivan Branković; Sander Ouburg; Servaas A Morré; Ekaterina S Jordanova
Journal:  J Immunol Res       Date:  2017-02-09       Impact factor: 4.818

9.  The SDF-1 rs1801157 Polymorphism is Associated with Cancer Risk: An Update Pooled Analysis and FPRP Test of 17,876 Participants.

Authors:  Xiang Tong; Yao Ma; Huajiang Deng; Xixi Wang; Sitong Liu; Zhipeng Yan; Shifeng Peng; Hong Fan
Journal:  Sci Rep       Date:  2016-06-06       Impact factor: 4.379

10.  Genetic variant in CXCL12 gene raises susceptibility to HPV infection and squamous intraepithelial lesions development: a case-control study.

Authors:  Nádia Calvo Martins Okuyama; Fernando Cezar-Dos-Santos; Érica Romão Pereira; Kleber Paiva Trugilo; Guilherme Cesar Martelossi Cebinelli; Michelle Mota Sena; Ana Paula Lombardi Pereira; Adriano Martin Felis Aranome; Luis Fernando Lasaro Mangieri; Rodolfo Sanches Ferreira; Maria Angelica Ehara Watanabe; Karen Brajão de Oliveira
Journal:  J Biomed Sci       Date:  2018-09-18       Impact factor: 8.410

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.